Trademarkia Logo

Canada

C$
Trademark Search in Canada
RA PHARMACEUTICALS

View On IC.GC.CA

RA PHARMACEUTICALS
REGISTERED

on 23 Sept 2019

Last Applicant/ Owned by

RA PHARMACEUTICALS INC.

87 Cambridge Park DriveCambridge, Massachusetts 02140

US

Serial Number

1789743 filed on 4th Jul 2016

Registration Number

TMA1055725 registered on 23rd Sept 2019

Registration expiry Date

23rd Sept 2029

Correspondent Address

SMART & BIGGAR LP

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOTTAWA

ONTARIO

CA

K1P5Y6

RA PHARMACEUTICALS

Trademark usage description

pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, namely for treating diabetic macular edema (d Read More

Classification Information

Class [005]
Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, namely for treating diabetic macular edema (DME), diabetic retinopathy, gout, lesions in lipopolysaccharides (LPS) diabetes, non proliferative diabetic retinopathy (DR), post operative ileus, proliferative diabetic retinopathy (PDR), scurvy, high blood pressure, hypertension, hypotension, anemia, atherosclerosis, cardiovascular disease, muscular dystrophy, the nervous system, namely, age-related macular degeneration (AMD), Alzheimer's disease, amyelotrophic lateral sclerosis (ALS), brain damage, brain edema, central serous retinopathy, chronic retinal detachment, dry age-related macular degeneration (AMD), Eals disease, Guillain-Barre syndrome (GBS), head trauma, Irvine Gass Syndrome, multiple sclerosis (MS), Myasthenia gravis, neurocognitive deficits, neuromyelitis optica (NMO), neuronal cell death, neuropathic pain, Parkinson's disease, radiation retinopathy, retinopathy of prematurity, spinal stenosis-degenerative spine disease, telangiectasis, traumatic brain injury, Von Hipple Lindau disease, wet age-related macular degeneration (AMD), the immune system, namely for treating anaphylaxis, anti-phospholipid syndrome (APS), autoimmune lymphoproliferative syndrome, autoimmune lymphoproliferative syndrome 4 (ALPS4), autoimmune uveitis, catastrophic anti-phospholipid syndrome (CAPS), cold agglutinin disease (CAD), complement disfunction, Crohn's disease, Guillain-Barre syndrome (GBS), inflammatory bowel disease, inflammatory pain, membranous glomerulonephritis (MGN), Myasthenia gravis, neuromyelitis optica (NMO), oral mucositis, osteoarthritis, paroxysmal nocturnal hemoglobinuria (PNH), Ras-associated autoimmune leukoproliferative disease, rheumatoid arthritis, sepsis, Sjorgren's syndrome, sterile inflammation, systemic inflammatory response syndrome, systemic lupus erythematosus (SLE), toxic shock, the cardio-vascular system, the respiratory system, the musculo-skeletal system, namely for treating, crush injuries, hip replacement complications, joint swelling, Myasthenia gravis, back pain, cartilage injuries, connective tissue diseases, fracture, spinal diseases, sprains, and the genitourinary system, namely for treating atypical hemolytic uremic syndrome (aHUS), hemodialysis complications, Lupus nephritis, membranous glomerulonephritis (MGN), renal failure, systemic lupus erythematosis nephritis, glomerulonephritis, hemolytic uremic syndrome, infertility, inflammatory pelvic diseases, megaureter, neurogenic bladder, sexually transmitted diseases, ureterocele or ureteral duplication, urological diseases, vesicoureteral reflux; pharmaceutical preparations, for human use, for the treatment of fibrotic disorders, namely, for treating coagulations from post fibrinolytic treatment conditions, fibrinolysis, aortic aneurysm, blood clotting, endothelial cell damage, heart vessel and valve abnormalities, hemorrhage, intracerebral hemorrhage (ICH), ischemia-reperfusion injury, restenosis, retinal hemorrhage, surgery-induced ischemia, transient ischemia attack (TIA), transvascular leakage, cirrhosis and inflammatory disorders, namely for treating acute lung injury, acute respiratory distress syndrome, adult respiratory distress syndrome (ARDS), anaphylaxis, anti-phospholipid syndrome (APS), asthma, autoimmune disease, autoimmune uveitis, catastrophic anti-phospholipid syndrome (CAPS), choroiditis, chronic obstructive pulmonary disease (COPD), cold agglutinin disease (CAD), complement disfunction, contact activation system (CAS) response, Crohn's disease, cytokine storm, dermatomyositis, drug-induced liver injury, febrile response, Guillain-Barre syndrome (GBS), inflammatory bowel disease, inflammatory pain, ischemia, membranous glomerulonephritis (MGN), multi-organ failure, Myasthenia gravis, neuromyelitis optica (NMO), oral mucositis, pancreatitis, periodontis, posterior uveitis, retinitis, rheumatoid arthritis, sepsis, Sjorgren's syndrome, sterile inflammation, systemic inflammatory response syndrome, systemic lupus erythematosus (SLE), toxic shock; pharmaceutical preparations, for human use, for use in dermatology, namely for treating hematoma, topical infections, anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, burn injury, chronic wounds, dermatomyositis, exanthema, wounds, sexually transmitted diseases, skin pigmentation disease, bacterial skin infections, dermatitis, fungal skin infections, parasitic skin infections, viral skin infections, nephrology, namely for treating anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, hemodialysis complications, Lupus nephritis, membranous glomerulonephritis (MGN), renal failure, renal transplantations, systemic lupus erythematosis nephritis, systemic lupus erythematosus (SLE), hepatology, namely for treating HELLP syndrome, Alagille Syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, biliary atresia, cirrhosis, galactosemia, Gilbert Syndrome, hemochromatosis, hepatic encephalopathy, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma, intrahepatic cholestasis of pregnancy (ICP), liver cancer, liver cysts, liver failure, liver transplant, lysosomal acid lipase deficiency (LAL-D), newborn jaundice, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Reye syndrome, type I glycogen storage disease, Wilson disease, rheumatology, namely for treating rheumatoid arthritis, osteoarthritis, Lupus, Sjorgren's syndrome, ankylosing spondylitis, oncology, namely for treating acral lentiginous melanoma, acute myelogenous leukemia (AML), adenoma, autoimmune lymphoproliferative syndrome, autoimmune lymphoproliferative syndrome 4 (ALPS4), bladder cancer, bone marrow cancer, chronic lymphocytic lymphoma, colorectal carcinoma, congenital somatic melanocytic nevus syndrome, Costello syndrome, ductal carcinoma of the pancreas, endometrial cancer, epidermal nevus, esophageal cancer, familial adenomatous polyposis, follicular thyroid cancer, gallbladder cancer, hyperproliferation disorders, juvenile myelomonocytic leukemia (JMML), kidney cancer, leukemias, lung adenocarcinoma, lung cancer, Lynch syndrome, malignant gastric cancer (GASC), melanoma, mucinous adenoma, myelodysplastic syndromescholangiocarcinoma, neuroblastoma, neurocutaneous melanosis, Noonan syndrome 1 (NS1), Noonan syndrome 3 (NS3), Noonan syndrome 6 (NS6), N-Ras-related Noonan syndrome, oral squamous cell carcinoma, ovarian cancer, pancreatic cancer, peri-tumor brain edema, pylocytic astrocytoma (PA), Ras-associated autoimmune leukoproliferative disease, thyroid cancer, tumor recurrence, vascular proliferative disorders, hematology, namely for treating anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, aortic aneurysm, arterial-venous malformation, atypical hemolytic uremic syndrome (aHUS), blood clotting, cardiofaciocutaneous syndrome 2 (CFC2), cold agglutinin disease (CAD), complement-dependent hemolysis, deep vein thrombosis (DVT), disseminated intravascular coagulation, disseminated intravascular coagulation (DIC), edema, endothelial cell damage, heart vessel and valve abnormalities, HELLP syndrome, hematopoietic stem cell transplantation (HSCT) issues, hemodialysis complications, hemolysis, hemolytic anemia, hemorrhage, hereditary angioedema (HAE), high blood pressure, hypertension, hypotension, intracerebral hemorrhage (ICH), ischemia-reperfusion injury, paroxysmal nocturnal hemoglobinuria (PNH), pathologic intraocular proliferation of retinal vessels, pediatric cardiac surgery, pre-eclampsia, pulmonary embolism, radiation-induced edema, restenosis, retinal edema, retinal hemorrhage, retinal non-perfusion, retinal vein occlusions, sickle cell retinopathy, stroke, surgery-induced ischemia, thrombocytopenia, thromboembolic stroke, thrombosis, thrombotic microangiopathy (TMA), transient ischemia attack (TIA), transvascular leakage, uncontrolled neovascularization, vasculitis, vasogenic cerebral edema, venous thrombosis, vitreous hemorrhage and in tissue and organ transplantation, namely, facial transplantation, heart valve transplantation, nerve transplantation, skin grafts, tendon transplantation, vein transplantation, orthotopic liver transplantation complications, renal transplantation complications, heart transplantation, intestinal transplantation, pancrease transplantation, thymus transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations, for human use, as anti-viral, anti-bacterial, or anti-fungal agents, namely for treating hepatitis B, hepatitis C, herpes, influenza, viral meningitis, bacterial meningitis, cholera, gastritis, staphylococcus infection, streptococcal infection, ulcers, whooping cough, coccidioidomycosis, C. neoformans infection, C. gattii infection, fungal eye infection, histoplasmosis, mucormycosis, pneumocystis pneumonia (PCP), ringworm, sporotrichosis.

Classification kind code

10

Class [042]
Pharmaceutical research and development in the field of peptides and peptidomimetics.

Classification kind code

10

Mark Details

Serial Number

1789743

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 27
on 21st Mar 2019		Approval Notice Sent
Submitted for opposition 12
on 27th Aug 2018		Extension of Time
Submitted for opposition 12
on 25th Jan 2018		Extension of Time
Submitted for opposition 12
on 22nd Aug 2017		Extension of Time
Submitted for opposition 22
on 20th Feb 2017		Search Recorded
Submitted for opposition 20
on 20th Feb 2017		Examiner's First Report
Submitted for opposition 135
on 15th Sept 2016		Amendment to Application
Submitted for opposition 31
on 12th Jul 2016		Formalized
Submitted for opposition 1
on 5th Jul 2016		Created
Submitted for opposition 30
on 4th Jul 2016		Filed